159 related articles for article (PubMed ID: 18209721)
1. Validation of a DNAemia cutoff for preemptive therapy of cytomegalovirus infection in adult hematopoietic stem cell transplant recipients.
Gerna G; Lilleri D; Caldera D; Furione M; Zenone Bragotti L; Alessandrino EP
Bone Marrow Transplant; 2008 May; 41(10):873-9. PubMed ID: 18209721
[TBL] [Abstract][Full Text] [Related]
2. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients.
Lilleri D; Baldanti F; Gatti M; Rovida F; Dossena L; De Grazia S; Torsellini M; Gerna G
J Med Virol; 2004 Jul; 73(3):412-8. PubMed ID: 15170637
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study.
Gerna G; Baldanti F; Torsellini M; Minoli L; Viganò M; Oggionnis T; Rampino T; Castiglioni B; Goglio A; Colledan M; Mammana C; Nozza F; Daniele L;
Antivir Ther; 2007; 12(1):63-72. PubMed ID: 17503749
[TBL] [Abstract][Full Text] [Related]
4. Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients.
Tormo N; Solano C; Benet I; Clari MA; Nieto J; de la Cámara R; López J; López-Aldeguer N; Hernández-Boluda JC; Remigia MJ; Garcia-Noblejas A; Gimeno C; Navarro D
Bone Marrow Transplant; 2010 Mar; 45(3):543-9. PubMed ID: 19617905
[TBL] [Abstract][Full Text] [Related]
5. Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.
Gerna G; Lilleri D; Zecca M; Alessandrino EP; Baldanti F; Revello MG; Locatelli F
Haematologica; 2005 Apr; 90(4):526-33. PubMed ID: 15820949
[TBL] [Abstract][Full Text] [Related]
6. Comparison of antigenemia assay and semiquantitative polymerase chain reaction test for monitoring active cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
Pajand O; Ziyaeyan M; Mousavi S; Fatolahzadeh B; Hojabri Z; Bahador A; Abdossamadi Z
Exp Clin Transplant; 2008 Jun; 6(2):149-54. PubMed ID: 18816243
[TBL] [Abstract][Full Text] [Related]
7. Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation.
Gerna G; Lilleri D; Callegaro A; Goglio A; Cortese S; Stroppa P; Torre G
Transplantation; 2008 Jul; 86(1):163-6. PubMed ID: 18622294
[TBL] [Abstract][Full Text] [Related]
8. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients.
Humar A; Lipton J; Welsh S; Moussa G; Messner H; Mazzulli T
Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322
[TBL] [Abstract][Full Text] [Related]
9. Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: a prospective, randomized, controlled, open-label trial.
Gerna G; Baldanti F; Lilleri D; Parea M; Torsellini M; Castiglioni B; Vitulo P; Pellegrini C; Viganò M; Grossi P; Revello MG
Transplantation; 2003 Apr; 75(7):1012-9. PubMed ID: 12698090
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the NucliSens CMV pp67 assay for detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation.
Hebart H; Rudolph T; Loeffler J; Middeldorp J; Ljubicic T; Jahn G; Einsele H
Bone Marrow Transplant; 2002 Aug; 30(3):181-7. PubMed ID: 12189537
[TBL] [Abstract][Full Text] [Related]
11. HHV-6-DNAemia related to CMV-DNAemia after liver transplantation.
Härmä M; Loginov R; Piiparinen H; Halme L; Höckerstedt K; Lautenschlager I
Transplant Proc; 2005 Mar; 37(2):1230-2. PubMed ID: 15848678
[TBL] [Abstract][Full Text] [Related]
12. Dynamics of cytomegalovirus (CMV) plasma DNAemia in initial and recurrent episodes of active CMV infection in the allogeneic stem cell transplantation setting: implications for designing preemptive antiviral therapy strategies.
Muñoz-Cobo B; Solano C; Costa E; Bravo D; Clari MÁ; Benet I; Remigia MJ; Montoro J; Navarro D
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1602-11. PubMed ID: 21871245
[TBL] [Abstract][Full Text] [Related]
13. Use of a DNAemia cut-off for monitoring human cytomegalovirus infection reduces the number of preemptively treated children and young adults receiving hematopoietic stem-cell transplantation compared with qualitative pp65 antigenemia.
Lilleri D; Gerna G; Furione M; Bernardo ME; Giorgiani G; Telli S; Baldanti F; Locatelli F
Blood; 2007 Oct; 110(7):2757-60. PubMed ID: 17579182
[TBL] [Abstract][Full Text] [Related]
14. Monitoring human cytomegalovirus infection in transplant recipients.
Baldanti F; Lilleri D; Gerna G
J Clin Virol; 2008 Mar; 41(3):237-41. PubMed ID: 18203657
[TBL] [Abstract][Full Text] [Related]
15. A prospective study comparing cytomegalovirus antigenemia, DNAemia and RNAemia tests in guiding pre-emptive therapy in thoracic organ transplant recipients.
Lehto JT; Lemström K; Halme M; Lappalainen M; Lommi J; Sipponen J; Harjula A; Tukiainen P; Koskinen PK
Transpl Int; 2005 Dec; 18(12):1318-27. PubMed ID: 16297050
[TBL] [Abstract][Full Text] [Related]
16. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease.
Bordon V; Bravo S; Van Renterghem L; de Moerloose B; Benoit Y; Laureys G; Dhooge C
Transpl Infect Dis; 2008 Feb; 10(1):19-23. PubMed ID: 17511814
[TBL] [Abstract][Full Text] [Related]
17. Monitoring HCMV infection with quantitative real-time PCR in HCMV-positive orthotopic liver transplant recipients, and predictive factors for treatment of the first episode of HCMV viremia.
Pillet A; Mengelle C; Basse G; Ribes D; Kamar N; Muscari F; Lavayssière L; Suc B; Esposito L; Peron JM; Rostaing L
Transplant Proc; 2006 Sep; 38(7):2335-8. PubMed ID: 16980083
[TBL] [Abstract][Full Text] [Related]
18. Human cytomegalovirus immediate-early mRNA detection by nucleic acid sequence-based amplification as a new parameter for preemptive therapy in bone marrow transplant recipients.
Gerna G; Baldanti F; Lilleri D; Parea M; Alessandrino E; Pagani A; Locatelli F; Middeldorp J; Revello MG
J Clin Microbiol; 2000 May; 38(5):1845-53. PubMed ID: 10790111
[TBL] [Abstract][Full Text] [Related]
19. Clinical trial of quantitative real-time polymerase chain reaction for detection of cytomegalovirus in peripheral blood of allogeneic hematopoietic stem-cell transplant recipients.
Cortez KJ; Fischer SH; Fahle GA; Calhoun LB; Childs RW; Barrett AJ; Bennett JE
J Infect Dis; 2003 Oct; 188(7):967-72. PubMed ID: 14513415
[TBL] [Abstract][Full Text] [Related]
20. Monitoring transplant patients for human cytomegalovirus: Diagnostic update.
Gerna G; Lilleri D
Herpes; 2006 May; 13(1):4-11. PubMed ID: 16732996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
